RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

Inclusion Criteria - Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB/IIIC not eligible for curative-intent therapies or stage IV/M1 (a/m NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2) - Aged at least 18 years at first diagnosis of a/m NSCLC - For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy. - For the non\_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC) - Patient must have received at least line of therapy of an active agent after failing PTC. Exclusion Criteria - Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts. - Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward. Always talk to your doctor about whether this trial is right for you.